An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany.
VERDICT
The label
Accumulation
read at $92.45
BioNTech SE ADR holds its Accumulation at $92.45.
PHPhase · the trend structure carries the Accumulation label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-29
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 3 days
Price
$92.45
Valuation
N/A trailing · -18.79 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.32
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$92.45
N/A P/E · -18.79 fwd
Our fair value
$127.92
38% discount
Analyst target (avg)
$127.92
+38% to current
Target low $75.82Analyst target rangeTarget high $154.29
▲ current $92.45 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$92.45
you are here
Conservative
$75.82
-18%
Analyst avg
$127.92
+38%
Our fair value
$127.92
+38%
Analyst high
$154.29
+67%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
-35.40%
Profit margin
-44.64%
Debt to equity
1.62
Analyst consensus
Buy · 20 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purity of revenue comes from non-compliant sources, over the 5% line.Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
COVID Boom Fades Into Oncology Wait
Picture the lab that delivered the first big mRNA shot now watching orders dry up. BioNTech still holds narrow expertise in personalised cancer vaccines, yet revenue has already dropped 35 percent and the firm is posting double-digit losses.
That leaves little reason to step in. Forward earnings sit negative, return on equity is negative too, and the narrow moat offers scant protection while oncology trials remain years from clear cash flow. Analysts may eye a higher price, but the business itself shows no durable edge today.
The main risks sit in trial setbacks and further revenue erosion once pandemic stockpiles end. Currency moves and German regulation add extra noise. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; its business and earnings are exposed to Germany and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADER
The trader read · the latest dated commentary
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (20 analysts) rates it buy, with a mean price target of $122. Entered 2026-07-23 · Markdown
JOURNAL
The dated journal · newest first, never edited
2026-07-23Markdown$91.48+1.0%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (20 analysts) rates it buy, with a mean price target of $122.
2026-07-18Markdown$90.54+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (20 analysts) rates it buy, with a mean price target of $122.
2026-07-03Markdown$90.54+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markdown$90.54Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$93.34
-7.9%
·
$921
-7.9%
2 months
$95.50
-10.0%
·
$900
-10.0%
3 months
$90.10
-4.6%
·
$954
-4.6%
6 months
$96.00
-10.5%
·
$895
-10.5%
1 year
$106.89
-19.6%
·
$804
-19.6%
2 years
$97.98
-12.3%
·
$877
-12.3%
3 years
$109.25
-21.3%
·
$787
-21.3%
5 years
$235.43
-63.5%
$2.11
$374
-62.6%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever BNTX does next, these words stay.
BioNTech SE ADR · BNTX · Accumulation · $92.45
Recorded 2026-07-29 · before the outcome · scored mechanically